Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S

Published: Thursday, May 09, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
TriLink BioTechnologies Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation. Their unique properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA may find applications wherever an enhanced Tm is required such as triplex formation or potentially even gene silencing.

"At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities. We appreciate being able to work with dedicated companies that hold high recognition in the market place. The market position as well as in depth knowledge of nucleic acids embedded within TriLink will enable us to further reach our goal," says Palle Schelde, CEO, Managing Director, QuantiBact.

"At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos," stated Richard Hogrefe, Ph.D., President and CEO of TriLink. "We are excited to work with the great folks at Quantibact and see how this technology might advance molecular diagnostics."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TriLink to Open New Early Phase Therapeutic Manufacturing Facility
Company's new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014.
Tuesday, May 27, 2014
TriLink Announces New License Agreement with Biofortuna
Agreement for use of CleanAmp™ dNTPs in Biofortuna’s freeze-drying contract development and production service.
Friday, November 08, 2013
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.
Thursday, May 16, 2013
TriLink BioTechnologies, Inc. Awarded European Patent
TriLink BioTechnologies, Inc. announces the award of their CleanAmp™ Primer patent by the European Patent Office (EPO Patent no. 2032714).
Tuesday, May 31, 2011
TriLink BioTechnologies, Inc. Announces License Agreement with Biofortuna Ltd
TriLink BioTechnologies, announced that it has signed a licensing agreement with Biofortuna Ltd. for use of CleanAmp™ dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits.
Tuesday, September 14, 2010
TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity
The National Institutes of Health recently awarded TriLink BioTechnologies, Inc. (TriLink) a Phase II SBIR Grant of approximately $725,000 to continue their work on developing reagents to enhance the specificity of DNA ligase.
Tuesday, June 22, 2010
TriLink BioTechnologies, Inc. Announces Supply Agreement with ETS Laboratories
TriLink BioTechnologies, Inc. (TriLink) announced that it has signed an agreement with ETS Laboratories (ETS) to supply CleanAmp™ dNTPs for use in their Scorpions™ Wine Spoilage Detection System.
Tuesday, April 27, 2010
Scientific News
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Diagnosing Bacterial Infections in Blood Samples
Researchers have diagnosed a bacterial infection from a blood sample in infants.
Neurodvelopmental Disorder Cause Linked to SON Gene
A genetic link has been discovered for a previously unxplained neurodevelopmental disorder.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Misdiagnosis in HCM Tests
Genetic tests for potentially fatal heart anomaly can misdiagnose condition in black Americans.
Computers Better Predict Lung Cancer Type, Severity
Study shows automating the analysis of cancer tissue samples increases the accuracy of tumor classification and patient prognoses.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Automating Genetic Analysis
Researchers are looking to have computers help perform genetic analysis when scientists study a patient's genome to diagnose a disease.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!